Ifetroban Sodium ( DrugBank: Ifetroban )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 85 | Idiopathic interstitial pneumonia | 1 |
85. Idiopathic interstitial pneumonia
Clinical trials : 627 / Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05571059 (ClinicalTrials.gov) | June 2023 | 27/9/2022 | Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF) | A Randomized, Double-Blind, Placebo-Controlled Phase II Study With an Open-Label Extension to Determine the Safety and Efficacy of Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | Drug: Ifetroban Sodium;Drug: Placebo | Cumberland Pharmaceuticals | NULL | Not yet recruiting | 40 Years | 80 Years | All | 128 | Phase 2 | NULL |